and wherein 1 or 2 H atoms may be replaced by A, OA, COA, CN, Hal, NO_2, OR^3, SOA and/or SO_2A,

Cyc denotes a 4-8 saturated carbocyclic ring optionally containing a group SO, SO_2, CO, and optionally substituted once or twice by a group selected from $CO(NR^3)_2$, and COHet, OR^3, Het^1, A, CH_2Het^1, NH_2, NHCOA, OCH_2Cyc^1 SO_2A and/or -SA(=NH)(=O),

Q denotes a linear or branched alkylene, having 1 to 6 carbon atoms wherein 1-5 H atoms may be replaced by a group independently selected from OR^3, Hal, $N(R^3)_2$, and wherein 1 or 2 CH_2 groups may be replaced by a group independently selected from CO, SO, SO_2 and NR_3, or Q denotes a 4-8-membered bivalent heterocyclic ring, which is saturated, unsaturated or aromatic and which contains 1 to 3 heteroatoms independently selected from N, O and S,

A denotes a linear or branched alkyl having 1 to 10 carbon atoms wherein 1 to 7 H atoms may be replaced by a group independently selected from $-OR^3$, Hal, $NHSO_2A$, SO_2A, SOA, $N(R^3)_2$, and wherein 1, 2 or 3 non-adjacent $-CH_2-$ groups may be replaced by a group independently selected from -CO-, NR^3 and/or -O-,

Hal denotes F, Cl, Br or I,

R^3 denotes H or C_1-C_6-alkyl wherein 1 H atom may be replaced by a group selected from OH, O-C_1-C_6-alkyl, and Hal,

Het^1 denotes a five- or six membered saturated monocyclic heterocycle which contains 1-3 N- and/or O-atoms, which optionally is monosubstituted by A,

Cyc^1 denotes cycloalkyl with 3-7 atoms, and stereoisomers thereof, including mixtures thereof in all ratios.

2. A compound of Formula (I) as defined in claim 1 wherein Z denotes one of the following groups:

289	2-trans-[4-(4-{2-[3-(1-Methyl-1H-pyrazol-4-yl)-phenyl]-pyrimidin-5-yl}-pyrazol-1-yl)-cyclohexylamino]-ethano
290	Trans-3-(4-{2-[3-(1-Methyl-1H-pyrazol-4-yl)-phenyl]-pyrimidin-5-yl}-pyrazol-1-yl)-cyclohexanol
291	4-(3-Methyl-4-{2-[3-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyrimidin-5-yl}-pyrazol-1-yl)-cyclohexanol
292	4-(4-{2-[2-Fluoro-5-(1-methyl-1H-pyrazol-4-yl)-phenyl]-pyrimidin-5-yl}-pyrazol-1-yl)-cyclohexanol

7. A compound of Formula (I) as defined in claims 1 to 6 and tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, for use as a medicament.

8. Use of a compound according to claim 1 for use in the manufacture of a medicament for the treatment or prevention of an inflammatory disease, autoimmune disorder, cancer or multiple.

9. A compound according to claim 8 wherein the autoimmune disease is selected from the group consisting of Asthma, Rheumatoid arthritis, Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS) , Autoimmune haemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Beh c;et's disease, Coeliac disease, Antitransglutaminase, Chagas disease, Chronic obstructive pulmonary disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1, Endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GB8), Hashimoto's disease, Hidradenitis suppurativa, Kawasa ki disease, IgA nephropathy, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid

arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Systemic sclerosis, Temporal arteritis, Ulcerative Colitis , Vasculitis , Vitiligo, Wegener's granulomatosis

10. A compound of claim 8 wherein the disease is selected from rheumathoid arthritis , lupus nephritis, systemic lupus erythematosus.

11. A compound of Formula (I) according to claim 1 for use in the prevention and/or treatment of the diseases associated to IRAK overexpression.

12. A kit consisting of separate packs of:

(a) an effective amount of a compound of the formula (I) and/or stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

13. A pharmaceutical composition containing at least one of the compounds of Formula (I) according to any one of claims 1 to 6.

14. A pharmaceutical composition according to claim 13 which additionally contains at least one further medicament used in the treatment of inflammatory diseases or immune disorders or immunomodulating agent.

15. A process for producing compounds of Formula (I) according to claims 1 to 6, comprising the step of reacting a compound of Formula (II)



(II)

wherein X denotes Hal or a triflate group and wherein R^1, R^a and Z are as defined in claim 1, with a compound of Formula (III)